ESMO

Perioperative Opdivo Extends Event-Free Survival in Lung Cancer

October 3rd 2024, 1:00pm

Article

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer

October 2nd 2024, 9:00pm

Article

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma

October 1st 2024, 9:00pm

Article

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney Cancer

October 1st 2024, 1:00pm

Article

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer

September 30th 2024, 9:00pm

Article

Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.

Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC

September 30th 2024, 1:00pm

Article

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Side Effects, Quality of Life Important to Consider in Breast Cancer Subset

September 29th 2024, 3:00pm

Article

Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

Cediranib Added to Lynparza Didn’t Improve Progression, Survival in Ovarian Cancer

September 26th 2024, 9:00pm

Article

A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.

Imjudo Plus Imfinzi Improve Survival Versus Nexavar in Liver Cancer

September 26th 2024, 1:00pm

Article

In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar.

Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma

September 25th 2024, 1:00pm

Article

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.